Clinical trials: BPH (Benign Prostatic Hyperplasia)
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptom
Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)
To evaluate the safety and efficacy of the Rezūm System and assess its effect on urinary symptoms secondary to benign prostatic hyperplasia (BPH).
- Trial name
- REZUM (NCT01912339)
- Testing
- Rezum System, Rigid Cystoscopy
- Where
- 15 sites in United States
- Volunteers
- 197 people
- Sponsor
- Boston Scientific Corporation
Prostatic Hyperplasia
Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment
This study will investigate the efficacy and safety of treatment with dutasteride and tamsulosin, administered once daily for 4 years, alone and in combination, on the improvement of symptoms and clinical outcome in men with…
- Trial name
- NCT00090103
- Testing
- dutasteride 0.5mg once daily for 4 years, tamsulosin 0.4mg once daily for 4 years
- Where
- 503 sites in United States, Argentina and 34 more
- Volunteers
- 4,844 people
- Sponsor
- GlaxoSmithKline
Prostatic Hyperplasia
Demonstrating the Clinical and Economic Benefit of 5 Alpha Reductase Inhibitor Adherence in Benign Prostatic Hyperplasia
This retrospective study aims to quantify the relationship between 5-alpha-reductase inhibitor (5ARI) adherence / length of therapy and the likelihood of acute urinary retention (AUR) or prostate surgery in patients with benign…
- Trial name
- NCT01334723
- Testing
- Adherent with 5-alpha-reductase inhibitor (5ARI) therapy, Non-adherent to 5ARI therapy
- Volunteers
- 35,032 people
- Sponsor
- GlaxoSmithKline
Benign Prostatic Hyperplasia
A Pilot Study Of The ALPFA Benign Prostatic Hyperplasia (BPH) Pulsed Field Ablation (PFA) System
The ALPFA Medical BPH Pilot Study is a prospective, open label, single arm pilot study to assess the use of the ALPFA BPH PFA System in the treatment of men over the age of 45 with obstructive urinary symptoms associated with…
- Trial name
- NCT06965582
- Testing
- ALPFA BPH PFA System
- Where
- 4 sites in Czechia, Italy and 1 more
- Volunteers
- 100 people
- Sponsor
- ALPFA Medical
BPH (Benign Prostatic Hyperplasia)
Prospective Post Market Clinical Registry for the Zenflow Spring System - A Minimally Invasive Treatment for LUTS Associated With BPH Spring System Registry
The purpose of this registry is to collect information on how the Zenflow Spring System works in everyday medical practice. The registry will track how the Spring System performs during the implant procedure, and at follow-up…
- Trial name
- NCT07538622
- Testing
- Zenflow Spring System
- Where
- 8 sites in United States
- Volunteers
- 300 people
- Sponsor
- Zenflow, Inc.
Prostatic Hyperplasia
Dutasteride in Enlarged Prostate Economic Assessment: A Retrospective Database Pooled Analysis of Early 5-alpha Reductase Inhibitor Use
This retrospective study aims to assess the economic impact of early initiation of 5-alpha-reductase inhibitor (5ARI) therapy in patients with enlarged prostate (EP) receiving 5ARI and alpha-blocker (AB) combination therapy.
- Trial name
- NCT01332435
- Testing
- 5ARI + AB
- Volunteers
- 6,896 people
- Sponsor
- GlaxoSmithKline
Overactive Bladder
Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia
This study will assess the long-term safety of vibegron when dosed up to 52 weeks in men with overactive bladder (OAB) symptoms on pharmacological therapy for Benign Prostatic Hyperplasia (BPH) who previously completed treatment…
- Trial name
- NCT04103450
- Testing
- Vibegron
- Where
- 35 sites in United States, Poland
- Volunteers
- 276 people
- Sponsor
- Urovant Sciences GmbH
Moderate-to-severe Benign Prostatic Hyperplasia (BPH)
Bioequivalence Study of AJU-G721 and G721R in Healthy Adult Volunteers Under Fasting Conditions
To evaluate and compare the safety and pharmacokinetic profiles of "AJU-G721" (test drug) and "G721R" (reference drug) in healthy adult male subjects.
- Trial name
- NCT07643220
- Testing
- Test Drug, Reference Drug
- Where
- South Korea
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- AJU Pharm Co., Ltd.
BPH Without Urinary Obstruction and Other Lower Urinary Tract Symptoms (LUTS)
The Effect of BRIZO on Lower Urinary Tract Symptoms (LUTS) Related to Benign Prostatic Hypertrophy (BPH)
A randomized, placebo controlled double-blind, 12-week treatment trial in men with moderate to severe symptoms of benign prostatic hyperplasia.
- Trial name
- NCT05227508
- Testing
- BRIZO
- Where
- Israel
- Volunteers
- 120 people
- Sponsor
- Se-cure Pharmaceuticals Ltd.
Prostatic Hyperplasia
Study to Characterise the Effect of Tamsulosin on Lower Urinary Tract Symptoms (LUTS) and Detrusor Motor Activity in Patients Affected by Benign Prostatic Hyperplasia (BPH) and Storage Urinary Symptoms
Study to evaluate the efficacy of tamsulosin on storage symptoms and detrusor motor activity in patients with LUTS suggestive of BPH and relevant storage symptoms
- Trial name
- NCT02245490
- Testing
- Tamsulosin HCl controlled release capsules
- Volunteers
- 153 people
- Sponsor
- Boehringer Ingelheim
Overactive Bladder, Urinary Urgency Incontinence
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
To assess the post-market clinical outcomes of the Axonics SNM System for treatment of overactive bladder in male patients.
- Conditions
- Overactive Bladder, Urinary Urgency Incontinence, Benign Prostatic Hyperplasia, Prostate Cancer
- Trial name
- NCT06511141
- Testing
- Axonics SNM System
- Where
- 23 sites in United States
- Volunteers
- 150 people
- Sponsor
- Axonics, Inc.
Prostatic Hyperplasia
Bioequivalence - Duodart Against Avodart & Omnic
Open-label, randomized, single dose, two-treatment, two-way crossover study
- Trial name
- NCT01657851
- Testing
- dutasteride/tamsulosin, dutasteride, tamsulosin
- Where
- Russia
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Phase 1, Healthy
EC905 Pharmacokinetic Profile Study
A study to compare the pharmacokinetics of tamsulosin HCl and solifenacin succinate after co-administration of single entity tablets and of the combination tablet EC905 under steady state conditions at three dose strengths.
- Conditions
- Phase 1, Healthy, Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
- Trial name
- NCT02634489
- Testing
- Tamsulosin HCl, Solifenacin Succinate, EC905
- Where
- Netherlands
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Prostatic Diseases
Benign Prostatic Hyperplasia in Taiwan
Primary Objective: To assess the sexual function of Benign Prostatic Hyperplasia patients Secondary Objective: To evaluate the association between Lower Urinary Tract Symptoms severity and sexual disorders To compare the sexual…
- Trial name
- NCT00941343
- Testing
- Alfuzosin (XATRAL® - SL770499)
- Where
- Taiwan
- Volunteers
- 362 people
- Sponsor
- Sanofi
Benign Prostatic Hyperplasia, Adenoma, Prostatic
Rezum FIM Optimization Study
Evaluate the effect of the NxThera BPH Rezum System on prostate tissue in subjects suffering from LUTS symptoms secondary to benign prostatic hyperplasia (BPH).
- Conditions
- Benign Prostatic Hyperplasia, Adenoma, Prostatic, Prostatic Adenoma, Prostatic Hyperplasia, Benign
- Trial name
- Rezum FIM (NCT02940392)
- Testing
- Rezum System
- Where
- Dominican Republic
- Volunteers
- 15 people
- Sponsor
- Boston Scientific Corporation
Benign Prostatic Hyperplasia
Efficacy and Safety of DKF-313 in Patients With Benign Prostatic Hyperplasia
This is a multi-center, randomized, double-blinded, double-dummy, parallel group, 48-week study to evaluated the efficacy and safety of DKF-313 (dutasteride and tadalafil) in patients with benign prostatic hyperplasia.
- Trial name
- NCT04947631
- Testing
- DKF-313, Dutasteride, Tadalafil
- Where
- South Korea
- Volunteers
- 667 people
- Sponsor
- Dongkook Pharmaceutical Co., Ltd.
Prostate Cancer
A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057
The purpose of this study is to test a novel diagnostic Positron Emission Tomography (PET) imaging agent for safety and biodistribution.
- Trial name
- NCT02916537
- Testing
- CTT1057, Prostatectomy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Cancer Targeted Technology
Erectile Dysfunction, Prostatic Hyperplasia
Pharmacokinetics and Safety of HCP1303 and Co-administration of HGP1201, HIP1402 in Healthy Male Volunteers
To investigate the pharmacokinetic properties and safety after administration of HCP1303 and co-administration of HGP1201, HIP1402 in healthy male volunteers
- Trial name
- NCT02712411
- Testing
- HCP1303, HGP1201, HIP1402
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Benign Prostatic Hyperplasia
Study to Treat Patients Who Have Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) With Tadalafil Daily
The purpose of this study is to determine whether an experimental drug known as tadalafil given once daily can reduce the symptoms associated with Benign Prostatic Hyperplasia (straining, urinary frequency, feeling like your…
- Trial name
- NCT00827242
- Testing
- tadalafil
- Where
- 27 sites in United States, Argentina and 3 more
- Volunteers
- 325 people
- Sponsor
- Eli Lilly and Company
Benign Prostatic Hyperplasia
Expander-2 Trial: Randomized Study to Evaluate Safety & Efficacy of the Urocross® Expander System & Retrieval Sheath
To demonstrate the safety and efficacy of the Urocross Expander System/Retrieval Sheath and the procedure to treat patients with symptomatic Benign Prostatic Hyperplasia (BPH).
- Trial name
- NCT05400980
- Testing
- Urocross implant
- Where
- 2 sites in United States
- Volunteers
- 240 people
- Sponsor
- Prodeon Medical, Inc